1-9 of 9
Jin Seok Ahn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong-Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3004–3016.
https://doi.org/10.1158/1078-0432.CCR-22-3901
Published: 15 August 2023
View articletitled, BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
Open the PDF for BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC

Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi, Se-Hoon Lee, Je-Gun Joung, Yeong Jeong Jeon, Jae Won Choi, Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Joungho Han, Woong-Yang Park, Jhingook Kim, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4312–4321.
https://doi.org/10.1158/1078-0432.CCR-22-0879
Published: 03 October 2022
View articletitled, Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
Open the PDF for Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC in another window
Includes: Supplementary data
Journal Articles

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

Hyun Ae Jung, Sehhoon Park, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2321–2328.
https://doi.org/10.1158/1078-0432.CCR-21-3646
Published: 01 June 2022
View articletitled, Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Open the PDF for Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study in another window
Includes: Supplementary data
Journal Articles

Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea

Hee Kyung Ahn, Soohyeon Lee, Seon-A Jang, Ji-Yeon Kim, Jin Seok Ahn, Yeon Hee Park
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): P20.
https://doi.org/10.1158/1557-3265.COVID-19-21-P20
Published: 15 March 2021
View articletitled, Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea
Journal Articles

Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su-Hyung Park, Keunchil Park, Myung-Ju Ahn, Eui-Cheol Shin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6610.
https://doi.org/10.1158/1078-0432.CCR-20-4231
Published: 15 December 2020
View articletitled, Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Open the PDF for Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors in another window
Journal Articles

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su-Hyung Park, Keunchil Park, Myung-Ju Ahn, Eui-Cheol Shin
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2144–2154.
https://doi.org/10.1158/1078-0432.CCR-18-1449
Published: 01 April 2019
View articletitled, The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Open the PDF for The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2139–2145.
https://doi.org/10.1158/1078-0432.CCR-15-1653
Published: 01 May 2016
View articletitled, A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Open the PDF for A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib in another window
Includes: Supplementary data
Journal Articles

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, Sang-We Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1307–1314.
https://doi.org/10.1158/1078-0432.CCR-09-1903
Published: 15 February 2010
View articletitled, Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Open the PDF for Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy in another window
Journal Articles

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

Myung-Ju Ahn, Byeong-Bae Park, Jin Seok Ahn, Sang We Kim, Heung-Tae Kim, Jong Seog Lee, Jin Hyung Kang, Jae Yong Cho, Hong Suk Song, Se Hoon Park, Chang Hak Sohn, Sang Won Shin, Jin Hyuck Choi, Chang-Seok Ki, Chan Keum Park, Alison J. Holmes, Pasi A. Jänne, Keunchil Park
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3860–3866.
https://doi.org/10.1158/1078-0432.CCR-07-4608
Published: 16 June 2008
View articletitled, Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Open the PDF for Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? in another window